Soliris, a drug distributed to treat rare disorders like Hemolytic-uremic syndrome and Paroxysmal nocturnal hemoglobinuria is currently being manufactured and developed by Alexion Pharmaceuticals.

The company is the only manufacturer of approved drugs for the two ultra-rare disorder that is life threatening and is the result of a genetic disorder. They are involved in various researches on the immune system while focusing on how it can be stopped from attacking healthy tissues.

Alexion is publicly traded on NASDAQ under the name ALXN and has been listed as No. 2 in Forbes’ World’s Most Innovative Companies. The sales of the company plummeted in 2012 mainly because of acquisition projects. They spent a huge amount of their sales in acquiring Enobia Pharma Corp. (Enobia) in February 7, 2012. The following day, they also acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On that same year as well, they spent on Asfotase alfa, another acquired asset.

Currently, the company employs a total of 1,373 employees and has been reportedly generating revenue of $1.13 billion. Their headquarters is in Cheshire, Connecticut.